Company news

Defence Therapeutics Inc news in 2025

Defence Therapeutics Inc's news releases, calls and decks from 2025, newest first.

View company

Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th

December 11, 2025

Defence Therapeutics Announces AGM Results and Provides Corporate Updates

December 10, 2025

Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs

December 4, 2025

Defence Therapeutics Announces Convertible Debenture Conversion

November 21, 2025

Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology

November 19, 2025

Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs

November 6, 2025

Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models

November 4, 2025

Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025

October 23, 2025

Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025

October 6, 2025

Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations

October 2, 2025

Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin

September 23, 2025

Defence Therapeutics Appoints Dr. Amie Phinney as Director

September 16, 2025

Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000

September 15, 2025

Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth

September 2, 2025

Defence Therapeutics Announces Debenture Units Financing

August 22, 2025

Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer

July 14, 2025

Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

June 9, 2025

Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub

June 2, 2025

Defence Therapeutics to Attend Bio International Convention in Boston, June 2025

May 28, 2025

Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies

April 8, 2025

Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer

March 26, 2025

Decks in 2025